Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FIRST WAVE BIOPHARMA, INC.

(FWBI)
  Report
Delayed Quote. Delayed Nasdaq - 12/03 04:00:01 pm
1.43 USD   -9.49%
11/30Health Care Stocks Slump With Market Tuesday
MT
11/30Health Care Stocks Dropping Tuesday
MT
11/30Wall Street Set to Open in Red Territory as Omicron Risks Hit Sentiment
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

First Wave BioPharma : Begins Patient Screening for Phase 2b Study of Niclosamide in Ulcerative Proctitis, Proctosigmoiditis

09/28/2021 | 09:45am EST


ę MT Newswires 2021
All news about FIRST WAVE BIOPHARMA, INC.
11/30Health Care Stocks Slump With Market Tuesday
MT
11/30Health Care Stocks Dropping Tuesday
MT
11/30Wall Street Set to Open in Red Territory as Omicron Risks Hit Sentiment
MT
11/30First Wave BioPharma Says Independent Committee Has Recommended Continuing Patient Enro..
MT
11/30First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive ..
AQ
11/30First Wave BioPharma, Inc. Announces Independent Data Monitoring Committee Provides Pos..
CI
11/29FIRST WAVE BIOPHARMA : Delisting/Failure to Satisfy Listing Rule/Transfer of Listing - For..
PU
11/29FIRST WAVE BIOPHARMA, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing..
AQ
11/16FIRST WAVE BIOPHARMA : ANNOUNCES RESTRUCTURING OF MERGER CONSIDERATION PAYMENT TERMS WITH ..
PU
11/16FIRST WAVE BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Regulation FD Dis..
AQ
More news
Analyst Recommendations on FIRST WAVE BIOPHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -59,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,24x
Yield 2021 -
Capitalization 17,8 M 17,8 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 12
Free-Float 99,4%
Chart FIRST WAVE BIOPHARMA, INC.
Duration : Period :
First Wave BioPharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FIRST WAVE BIOPHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 1,43 $
Average target price 16,00 $
Spread / Average Target 1 019%
EPS Revisions
Managers and Directors
James E. Sapirstein Chairman, President & Chief Executive Officer
Daniel H. Schneiderman Chief Financial Officer
James E. Pennington Chief Medical Officer
Edward J. Borkowski Lead Independent Director
Charles J. Casamento Independent Director
Sector and Competitors
1st jan.Capi. (M$)
FIRST WAVE BIOPHARMA, INC.-85.26%18
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298